» Articles » PMID: 34014512

Electrocardiographic Parameters of Left Ventricular Hypertrophy and Prediction of Mortality in Hemodialysis Patients

Abstract

Background: In hemodialysis patients, left ventricular hypertrophy (LVH) contributes to high cardiovascular mortality. We examined cardiovascular mortality prediction by the recently proposed Peguero-Lo Presti voltage since it identifies more patients with electrocardiographic (ECG) LVH than Cornell or Sokolow-Lyon voltages.

Methods: A total of 308 patients on hemodialysis underwent 24 h ECG recordings. LVH parameters were measured before and after dialysis. The primary endpoint of cardiovascular mortality was recorded during a median 3-year follow up. Risk prediction was assessed by Cox regression, both unadjusted and adjusted for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score.

Results: The Peguero-Lo Presti voltage identified with 21% the most patients with positive LVH criteria. All voltages significantly increased during dialysis. Factors such as ultrafiltration rate, Kt/V, body mass index, sex, and phosphate were the most relevant for these changes. During follow-up, 26 cardiovascular deaths occurred. Post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages were independently associated with cardiovascular mortality in unadjusted and adjusted analysis. The Sokolow-Lyon voltage was not significantly associated with mortality. An optimal cut-off for the prediction of cardiovascular mortality was estimated at 1.38 mV for the Peguero-Lo Presti.

Conclusions: The post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages allowed independent risk prediction of cardiovascular mortality in hemodialysis patients. Measuring the ECG LVH parameters after dialysis might allow a standardized interpretation as dialysis-specific factors influence the voltages.

Citing Articles

Effects of high-sensitivity C-reactive protein and left ventricular hypertrophy on cognitive function in hemodialysis patients.

Zhang Y, Gu Y, Zhang W, Li X, Xu L, Liu T Ren Fail. 2025; 47(1):2450522.

PMID: 39819254 PMC: 11749012. DOI: 10.1080/0886022X.2025.2450522.


Clinical utility of electrocardiographic voltage parameters for the diagnosis of hypertrophic cardiomyopathy.

Li G, Jin L, Weng Z, Jin X, Lin X, Chen S Front Cardiovasc Med. 2024; 11:1354364.

PMID: 39386386 PMC: 11462641. DOI: 10.3389/fcvm.2024.1354364.


The prevalence and risk of mortality associated with intradialytic hypertension among patients with end-stage kidney disease on haemodialysis: A systematic review and meta-analysis.

Adejumo O, Edeki I, Oyedepo D, Yisau O, Ige O, Ekrikpo I PLoS One. 2024; 19(6):e0304633.

PMID: 38861528 PMC: 11166311. DOI: 10.1371/journal.pone.0304633.


Do We Need New Electrocardiographic Criteria for Left Ventricular Hypertrophy? The Case of the Peguero-Lo Presti Criterion. A Narrative Review.

Faggiano A, Gherbesi E, Tadic M, Carugo S, Grassi G, Cuspidi C Am J Hypertens. 2023; 37(3):155-162.

PMID: 38112655 PMC: 10906064. DOI: 10.1093/ajh/hpad117.


Prognostic values of left ventricular mass index progression in incident peritoneal dialysis patients : a prospective cohort study.

Chen Y, Dai S, Ge X, Shang D, Xie Q, Hao C BMC Nephrol. 2022; 23(1):200.

PMID: 35641920 PMC: 9158358. DOI: 10.1186/s12882-022-02831-6.

References
1.
Culleton B, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R . Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007; 298(11):1291-9. DOI: 10.1001/jama.298.11.1291. View

2.
McCullough P, Chan C, Weinhandl E, Burkart J, Bakris G . Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016; 68(5S1):S5-S14. DOI: 10.1053/j.ajkd.2016.05.025. View

3.
Gong I, Al-Amro B, Prasad G, Connelly P, Wald R, Wald R . Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. J Cardiovasc Magn Reson. 2018; 20(1):83. PMC: 6296102. DOI: 10.1186/s12968-018-0504-5. View

4.
Charytan D . Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014; 23(6):578-85. PMC: 4266593. DOI: 10.1097/MNH.0000000000000067. View

5.
Kovesdy C, Quarles L . Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant. 2013; 28(9):2228-36. PMC: 3769978. DOI: 10.1093/ndt/gft065. View